Microbot Medical (MBOT) to Release Earnings on Tuesday

Microbot Medical (NASDAQ:MBOT) is expected to issue its results before the market opens on Tuesday, March 24th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.1130 million for the quarter.

Microbot Medical Trading Up 1.5%

NASDAQ:MBOT opened at $2.73 on Tuesday. The company’s 50 day moving average is $2.17 and its two-hundred day moving average is $2.48. The company has a market cap of $183.35 million, a PE ratio of -6.07 and a beta of 1.22. Microbot Medical has a twelve month low of $1.35 and a twelve month high of $4.67.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. American Century Companies Inc. acquired a new stake in Microbot Medical in the 2nd quarter valued at $32,000. Zacks Investment Management purchased a new position in Microbot Medical during the third quarter valued at $33,000. Man Group plc acquired a new stake in shares of Microbot Medical in the fourth quarter valued at about $35,000. Squarepoint Ops LLC purchased a new stake in shares of Microbot Medical during the third quarter worth about $37,000. Finally, XTX Topco Ltd acquired a new position in shares of Microbot Medical during the 2nd quarter worth about $43,000. 16.30% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Roth Mkm assumed coverage on Microbot Medical in a research note on Wednesday, December 3rd. They issued a “buy” rating and a $5.50 target price for the company. B. Riley Financial began coverage on Microbot Medical in a report on Tuesday, February 10th. They set a “buy” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Microbot Medical in a research report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Microbot Medical has an average rating of “Moderate Buy” and an average target price of $7.50.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.